Investment Analysts’ updated eps estimates for Monday, November 18th:
Aclaris Therapeutics (NASDAQ:ACRS) was upgraded by analysts at Piper Sandler from a neutral rating to an overweight rating. Piper Sandler currently has $13.00 price target on the stock, up from their previous price target of $3.00.
Alnylam Pharmaceuticals (NASDAQ:ALNY) had its overweight rating reiterated by analysts at Piper Sandler. Piper Sandler currently has a $296.00 target price on the stock.
Blueprint Medicines (NASDAQ:BPMC) had its market outperform rating reiterated by analysts at JMP Securities. The firm currently has a $125.00 target price on the stock.
Larimar Therapeutics (NASDAQ:LRMR) had its buy rating reaffirmed by analysts at HC Wainwright. The firm currently has a $15.00 target price on the stock.
ModivCare (NASDAQ:MODV) had its outperform rating reiterated by analysts at Barrington Research. They currently have a $25.00 price target on the stock.
Simplify Exchange Traded Funds (TSE:PINK) was upgraded by analysts at Raymond James from a market perform rating to an outperform rating. Raymond James currently has C$1.50 target price on the stock, up from their previous target price of C$1.00.
SmartCentres Real Estate Investment Trst (TSE:SRU.UN) was upgraded by analysts at TD Securities from a hold rating to a buy rating. The firm currently has C$28.00 price target on the stock, up from their previous price target of C$26.00.
STERIS (NYSE:STE) had its market outperform rating reaffirmed by analysts at JMP Securities. The firm currently has a $265.00 price target on the stock.
Walmart (NYSE:WMT) had its target price increased by Royal Bank of Canada from $88.00 to $92.00. The firm currently has an overweight rating on the stock.
Walmart (NYSE:WMT) had its price target boosted by Evercore ISI from $66.00 to $89.00. They currently have an overweight rating on the stock.
Receive News & Ratings for Aclaris Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.
